知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

133 条记录 (耗时 0.036 秒)

    Improved Human Herpesvirus Immunotherapy
    11.
    发明申请
    Improved Human Herpesvirus Immunotherapy 有权
    改善人类疱疹病毒免疫治疗

    公开(公告)号：US20150273051A1

    公开(公告)日：2015-10-01

    申请号：US14436239

    申请日：2013-10-21

    申请人： THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH

    发明人： Rajiv Khanna ,  Dasari Vijayendra

    IPC分类号： A61K39/245 ,  C12N7/00 ,  C12N5/0783 ,  C07K14/005

    CPC分类号： A61K39/245 ,  A61K2039/572 ,  A61K2039/6031 ,  A61K2039/70 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/40 ,  C12N5/0638 ,  C12N7/00 ,  C12N2501/998 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2710/16222 ,  C12N2710/16234

    摘要： An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.

    摘要翻译： 分离的蛋白质包含来自两种或多种不同疱疹病毒抗原的多个CTL表位中的每一个的相应氨基酸序列，并且还包含至少两个所述CTL表位之间的插入氨基酸或氨基酸序列，其包含蛋白酶体释放氨基酸或氨基酸 序列和任选的与抗原加工识别基序相关的转运蛋白。 分离的蛋白质能够在体外迅速膨胀人细胞毒性T淋巴细胞（CTL），并在作为外源蛋白质给予动物时在体内引发CTL免疫应答。 通常，分离的蛋白质包含不超过二十（20）个源自巨细胞病毒和/或爱泼斯坦 - 巴尔病毒抗原的CTL表位。

    EPSTEIN-BARR-VIRUS VACCINE
    14.
    发明申请
    EPSTEIN-BARR-VIRUS VACCINE 审中-公开

    公开(公告)号：US20140227305A1

    公开(公告)日：2014-08-14

    申请号：US13818711

    申请日：2011-08-25

    申请人： Romana Lange-Ruiss ,  Gilbert Reisbach ,  Wolfgang Hammerschmidt ,  Reinhard Zeidler

    发明人： Romana Lange-Ruiss ,  Gilbert Reisbach ,  Wolfgang Hammerschmidt ,  Reinhard Zeidler

    IPC分类号： A61K39/245

    CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C07K2317/569 ,  C12N7/00 ,  C12N2710/16223 ,  C12N2710/16234 ,  C12N2710/16252 ,  C12N2710/16262 ,  C12N2710/16271

    摘要： The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and/or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according to the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.

    摘要翻译： 本发明涉及包含颗粒的疫苗，所述颗粒包含（i）至少一种爱泼斯坦 - 巴尔病毒（EBV）结构多肽，（ii）至少一种EBV溶解多肽，（iii）膜脂质，所述颗粒无缺陷 的EBV DNA，其中（a）包含在所述颗粒中的B细胞转化所需的一种或多种EBV多肽的B细胞转化能力在其免疫原性保持时被禁用; 和/或（b）所述颗粒缺乏B细胞转化所需的一种或多种EBV多肽。 此外，本发明涉及一种生成颗粒的方法，本发明方法获得的细胞包含根据本发明方法生成的疫苗或颗粒的试剂盒。 此外，本发明涉及根据本发明的方法产生的疫苗或颗粒用于产生对EBV抗原特异性的CD8 +细胞的用途。

    Direct vaccination of the bone marrow
    15.
    发明申请
    Direct vaccination of the bone marrow 审中-公开
    直接接种骨髓

    公开(公告)号：US20090130144A1

    公开(公告)日：2009-05-21

    申请号：US11911618

    申请日：2006-04-14

    申请人： Scott E. Strome ,  Xiaoyu Zhang

    发明人： Scott E. Strome ,  Xiaoyu Zhang

    IPC分类号： A61K39/12 ,  A61K39/00 ,  A61K39/07 ,  C12N5/08

    CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/70 ,  C12N2710/16134 ,  C12N2710/16234 ,  C12N2760/16134

    摘要： The present invention provides methods for eliciting an effective immune response against a weakly immunogenic disease or for priming T cells to become memory T cells against a weakly immunogenic disease by directly vaccinating into the bone marrow of the patient an antigen associated with the weakly immunogenic disease. Also included in the present invention is an isolated population of human memory CD8+ T cells from the bone marrow which is in a heightened activation state with a unique effector phenotype.

    摘要翻译： 本发明提供了针对弱免疫原性疾病引发有效的免疫应答或通过直接接种到患者的骨髓中与弱免疫原性疾病相关的抗原来引发T细胞成为抵抗弱免疫原性疾病的记忆性T细胞的方法。 本发明还包括来自骨髓的人类记忆CD8 + T细胞的分离群体，其处于具有独特效应物表型的更高活化状态。

    Assays and therapies for latent viral infection
    17.
    发明授权
    Assays and therapies for latent viral infection 失效
    潜伏病毒感染的检测和疗法

    公开(公告)号：US06642008B1

    公开(公告)日：2003-11-04

    申请号：US09718693

    申请日：2000-11-22

    申请人： John B. Harley ,  Judith Ann James ,  Kenneth M. Kaufman

    发明人： John B. Harley ,  Judith Ann James ,  Kenneth M. Kaufman

    IPC分类号： G01N3353

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/545 ,  A61K2039/55566 ,  C07K16/085 ,  C12N2710/16222 ,  C12N2710/16234 ,  Y02A50/386 ,  Y02A50/414

    摘要： Compositions that bind specific viral proteins expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for infected cell removal. These antibodies can distinguish cells expressing EBV DNA from cells which do not. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also discloset. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people harboring latent viral particles. The antibody conjugates can also be used to remove infected cells or kill the infected cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who risk developing autoimmune diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).

    摘要翻译： 公开了在病毒生命周期潜伏期期间结合特异性病毒蛋白质的组合物。 这些组合物结合潜在的病毒蛋白质，同时病毒蛋白质在其细胞宿主中表达，并提供靶向隐藏潜伏病毒的细胞的手段。 在优选的实施方案中，组合物是结合潜在病毒蛋白的细胞外区域，最优选LMP-2A，与诊断或细胞毒性剂缀合或固定在固体支持物上用于感染细胞去除的EBV潜伏蛋白的抗体。 这些抗体可以区分表达EBV DNA的细胞与不具有细胞的细胞。 还可以公开可用于引发这些抗体或疫苗生产的组合物。 还公开了用于产生诊断或细胞毒性试剂和基于鉴定潜在病毒的细胞的病毒表位的疫苗的方法。 抗体缀合物可用于诊断测定以鉴定表达潜伏性病毒蛋白的细胞和携带潜伏病毒颗粒的人群。 抗体缀合物也可用于去除感染的细胞或杀死被感染的细胞。 或者或另外，病毒蛋白质或其部分可以用作疫苗以诱导宿主杀死受感染细胞的免疫反应。 这些方法可用于检测或治疗患有潜伏病毒如EBV的患者，以及患有发展自身免疫性疾病如系统性红斑狼疮（SLE）或类风湿性关节炎（RA）的患者。

    Virus vaccines
    19.
    发明授权
    Virus vaccines 失效
    病毒疫苗

    公开(公告)号：US5976552A

    公开(公告)日：1999-11-02

    申请号：US430971

    申请日：1995-04-28

    申请人： Franklin Volvovitz

    发明人： Franklin Volvovitz

    IPC分类号： A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K39/165 ,  A61K39/245 ,  A61K39/25 ,  A61P31/12 ,  C12N15/63

    CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K39/155 ,  A61K39/165 ,  A61K39/245 ,  A61K39/25 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/70 ,  C12N2710/16234 ,  C12N2710/16634 ,  C12N2710/16734 ,  C12N2760/16034 ,  C12N2760/18434 ,  C12N2760/18534

    摘要： Improved mammalian virus vaccines are combinations that contain an immunogenic amount of inactivated virus, such as influenza virus, Herpes varicella virus, measles virus, Epstein Barr virus, respiratory syncytial virus, parainfluenza 3, Herpes simplex type 1 virus, and Herpes simplex type 2 virus, and an immunogenic amount of a purified recombinant envelope protein from the virus, or a fragment or precursor of the protein. Alternatively, they contain either inactivated virus and/or envelope protein antigens and an adjuvant such as granulocyte-microphage colony stimulating factor. One embodiment of an influenza vaccine is prepared by combining inactivated virus, preferably three strains of the virus, and hemagglutinin, preferably a combination of respective hemagglutinins for each of the three strains present. In another embodiment, an influenza vaccine is prepared by combining inactivated virus, again preferably three strains of the virus, and neuraminidase, preferably a combination of respective neuraminidase for each of the three strains present. In a third embodiment, the vaccine contains inactivated virus and both hemagglutinin and neuraminidase, preferably using three strains of each. Granulocyte-macrophage colony stimulating factor is, optionally, added to these embodiments.

    摘要翻译： 改进的哺乳动物病毒疫苗是含有免疫原性量的灭活病毒的组合，例如流感病毒，水痘病毒，麻疹病毒，爱泼斯坦巴尔病毒，呼吸道合胞病毒，副流感3，单纯疱疹1型病毒和2型单纯疱疹病毒 ，以及免疫原性量的来自病毒的纯化重组包膜蛋白，或蛋白质的片段或前体。 或者，它们包含灭活的病毒和/或包膜蛋白抗原和佐剂，例如粒细胞 - 微噬菌体集落刺激因子。 流感疫苗的一个实施方案是通过将存在的三种菌株中的每一种组合灭活的病毒，优选三种病毒和血凝素，优选各自血凝素的组合来制备。 在另一个实施方案中，流感疫苗是通过将灭活的病毒，再次优选三种病毒和神经氨酸酶组合制备的，优选地，存在三种菌株中的每一种的各自的神经氨酸酶的组合。 在第三个实施方案中，疫苗含有灭活病毒和血细胞凝集素和神经氨酸酶，优选使用各自的三个菌株。 粒细胞 - 巨噬细胞集落刺激因子任选地添加到这些实施方案中。